Celldex Therapeutics, Inc. (NASDAQ:CLDX) Short Interest Update

Celldex Therapeutics, Inc. (NASDAQ:CLDX) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 8,244,450 shares, a growth of 20.1% from the December 15th total of 6,865,432 shares. Based on an average daily trading volume, of 672,703 shares, the days-to-cover ratio is presently 12.3 days. Currently, 13.0% of the shares of the stock are short sold. Currently, 13.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 672,703 shares, the days-to-cover ratio is presently 12.3 days.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Mizuho initiated coverage on Celldex Therapeutics in a report on Tuesday, October 21st. They set an “outperform” rating and a $48.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Wednesday, October 8th. Finally, Barclays boosted their price objective on shares of Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a research report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $44.10.

Insider Transactions at Celldex Therapeutics

In other news, insider Richard M. Wright sold 49,298 shares of Celldex Therapeutics stock in a transaction that occurred on Thursday, November 13th. The shares were sold at an average price of $24.00, for a total transaction of $1,183,152.00. Following the completion of the sale, the insider directly owned 20,833 shares in the company, valued at approximately $499,992. This trade represents a 70.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.40% of the company’s stock.

Institutional Trading of Celldex Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Aster Capital Management DIFC Ltd acquired a new stake in Celldex Therapeutics during the third quarter worth about $26,000. Nisa Investment Advisors LLC increased its position in Celldex Therapeutics by 171.7% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 881 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in Celldex Therapeutics in the third quarter valued at approximately $42,000. Russell Investments Group Ltd. lifted its position in Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 501 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Celldex Therapeutics during the third quarter worth approximately $63,000.

Celldex Therapeutics Trading Down 0.2%

Shares of NASDAQ:CLDX traded down $0.04 on Monday, hitting $25.65. The company had a trading volume of 675,539 shares, compared to its average volume of 707,785. The company has a market cap of $1.70 billion, a PE ratio of -7.59 and a beta of 1.19. Celldex Therapeutics has a 52-week low of $14.40 and a 52-week high of $30.50. The business has a 50 day moving average of $26.48 and a 200 day moving average of $24.93.

Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.13). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 33.22%. As a group, equities analysts predict that Celldex Therapeutics will post -2.48 EPS for the current year.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.